Indivior PLC Board of Directors

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Mr. Mark Crossley

Mr. Mark Crossley

CEO & Executive Director

Mr. Richard Simkin

Mr. Richard Simkin

Chief Commercial Officer

Ms. Angela Colon-Mahoney M.S.

Ms. Angela Colon-Mahoney M.S.

Chief Human Resources Officer

Dr. Christian Heidbreder

Dr. Christian Heidbreder

Chief Scientific Officer

Ms. Cynthia Cetani

Ms. Cynthia Cetani

Chief Integrity & Compliance Officer

Mr. Hillel West

Mr. Hillel West

Chief Manufacturing & Supply Officer

Mr. Ryan Preblick

Mr. Ryan Preblick

Chief Financial Officer

Mr. Jason Thompson

Mr. Jason Thompson

Vice President of Investor Relations

Mr. Vishal Kalia

Mr. Vishal Kalia

SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.